CAR-TCR Summit Europe 2021 and Car Tcr Summit Europe 2021 View overview page

2:49
Exciting advances in CAR-T and TCR research
David Gilham • 22 Feb 2021
1:40
Innovations within the CAR T-cell field
Hong Ma • 19 Feb 2021
2:56
Allogenic NKX101 in r/r AML
James Trager • 22 Feb 2021
6:05
Selecting TCRs: understanding peptide-HLA-TCR interactions
Dolores Schendel • 25 Feb 2021
8:28
Investigating allogeneic iNKT cell therapy
Marc van Dijk • 23 Feb 2021
6:34
Combining iNKT and CAR technology
Marc van Dijk • 23 Feb 2021
3:23
How the TCR field can learn from CARs
Dolores Schendel • 25 Feb 2021
5:11
PD1-41BB switch receptor expression in the treatment of PD-L1-positve solid tumors
Dolores Schendel • 25 Feb 2021
3:05
Targetting cancer with allogeneic NK cell therapies
James Trager • 10 Mar 2021
2:09
CAR-NKs for B cell malignancies
James Trager • 10 Mar 2021
1:45
Automated cell culture in cell & gene therapy
Dalip Sethi • 23 Feb 2021
3:24
CYAD-101 & alloSHRINK: allogeneic CAR-T cell therapy in MSS mCRC
David Gilham • 22 Feb 2021
4:15
CT053, anti-GPC3 CAR-T and targeting solid tumors
Hong Ma • 19 Feb 2021
2:43
Automation in cell therapy manufacturing: enhancing the fill and finish step
Dalip Sethi • 23 Feb 2021
3:28
Analysing trends in the CAR-TCR landscape
Vasiliki Zochiou • 22 Feb 2021
2:29
CYCLE-1: next generation NKG2D-based CAR T-cells in AML/MDS
David Gilham • 22 Feb 2021
The content of VJRegenMed is intended for healthcare professionals